NOV 28, 2015 11:17 AM PST

New Drug Regimen for Metastatic Prostate Cancer

WRITTEN BY: Xuan Pham
Doctors at the University of Montreal Hospital Research Centre (CRCHUM) have announced the start of a Phase 3 clinical trial for a new drug combination in the treatment of metastatic prostate cancer. With initial results from Phase 1 and 2 showing effectiveness, the researchers will move the drug therapy into Phase 3 that will involve 960 patients worldwide.
 
New drug combination to treat prostate cancer

Prostate cancer is the most common form of cancer in men. Current treatments for the disease frequently involve radiation and chemotherapy, hormone interventions, or surgical removal of the prostate itself. With early detection and treatment, prostate cancer is manageable. However, this is not the case for patients with castration-resistant metastatic prostate cancer.
 
In this aggressive form of prostate cancer, the disease progresses despite all medical interventions. The tumors are resistant to hormone therapies, and metastasis to secondary organ sites compound the difficulties in treatment, worsening the prognosis dramatically.
 
Medical options are limited for this subset of prostate cancer, but one type of drug that has been used since 2011 is abiraterone acetate, marketed under the tradename Zytiga. Taken orally in addition to hormone administration, the combination blocks the production of testosterone, decreasing tumor growth.
 
Doctors then tested abiraterone acetate in combination with another drug not yet approved for market, and known only as JNJ-56021927. Initial clinical trials of this combination provided evidence for the safety and effectiveness of the new drug therapy.
 
A patient from the initial trials at CRCHUM, Antonio Paris, 59, attested to the effectiveness of his new drug regimen: "I take 14 pills a day, and it's going very well. I have the sweats and I'm tired a bit, but it doesn't stop me from doing all kinds of activities and even renovations. Since I started the new treatment 14 months ago, my cancer first remitted and now is stable.”
 
The results won the green light from the U.S. Food and Drug Administration and Health Canada for the trial to enter Phase 3. The randomized, double blind trial will involve 960 patients from 196 hospitals worldwide. Patients will either be administered abiraterone acetate (1000 mg) and JNJ-56021927 (240 mg) or a placebo.
 
"We hope to find a well-tolerated and effective treatment to slow the progression of prostate cancer in men with advanced prostate cancer. The approach combines several drugs and attacks the cancer on several fronts," said Dr. Fred Saad, lead investigator of the study.
 
It will be another few years before this international trial completes and results are publicized. But the doctors and researchers are very enthusiastic that this combination drug therapy will extend life expectancy and improve the quality of life for their patients.

Watch the animation to learn more about prostate cancer.

Source: EurekAlert
 
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 07, 2020
Clinical & Molecular DX
Saliva Test for Early Detection of Mouth and Throat Cancer
JAN 07, 2020
Saliva Test for Early Detection of Mouth and Throat Cancer
“OPC is one of the fastest rising cancers in Western countries due to increasing HPV-related incidence, especially ...
JAN 13, 2020
Chemistry & Physics
Magnetic Field-guided Tethered-probe Can Navigate Complex Vascular Networks
JAN 13, 2020
Magnetic Field-guided Tethered-probe Can Navigate Complex Vascular Networks
Deep and complex vasculatures such as carotid arteries represent a challenge for diagnosis and treatment because they ar ...
FEB 07, 2020
Clinical & Molecular DX
New diagnostic technology uses levitating proteins
FEB 07, 2020
New diagnostic technology uses levitating proteins
Intrinsic biophysical properties of proteins hold valuable clues about how they function and their role in disease. Take ...
APR 21, 2020
Immunology
Sino Biological Focuses on Serological Studies of COVID-19
APR 21, 2020
Sino Biological Focuses on Serological Studies of COVID-19
April 17, 2020, Sino Biological announced this week that the company launched the world’s first coronavirus antige ...
APR 29, 2020
Clinical & Molecular DX
Move and Detect : Diagnosis of Neonatal Sepsis Using Fluorescent Micromotors
APR 29, 2020
Move and Detect : Diagnosis of Neonatal Sepsis Using Fluorescent Micromotors
According to the World Health Organization (WHO), sepsis occurs when the body’s response to an infection injures i ...
JUN 04, 2020
Clinical & Molecular DX
Low T Cells Linked To High COVID Risk
JUN 04, 2020
Low T Cells Linked To High COVID Risk
  German scientists have found a link between immune cell counts and the risk of developing severe, potentially lif ...
Loading Comments...